Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

癌細胞増殖阻害剤の世界市場:チロシンキナーゼ阻害薬、HDAC阻害薬、MTORタンパク質阻害薬、PI3K阻害薬、プロテアソーム阻害薬

◆タイトル:Cancer Growth Inhibitors Market & Clinical Pipeline Analysis
◆商品コード:KUICK504221
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年4月
◆ページ数:1000
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,400 ⇒換算¥266,400見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD4,800 ⇒換算¥532,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、癌細胞増殖阻害剤の世界市場について調査・分析し、以下の構成でお届けいたします。

・癌細胞増殖阻害剤の概要
・癌細胞増殖阻害剤治療の仕組み
・癌細胞増殖阻害剤の世界市場概要
・癌細胞増殖阻害剤の世界市場動態
・癌細胞増殖阻害剤の世界市場展望
・チロシンキナーゼ阻害薬の開発パイプライン(治験)動向
・HDAC阻害薬の開発パイプライン(治験)動向
・MTORタンパク質阻害薬の開発パイプライン(治験)動向
・PI3K阻害薬の開発パイプライン(治験)動向
・プロテアソーム阻害薬の開発パイプライン(治験)動向
・主要企業分析

Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.

Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.

Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.

Cancer Growth Inhibitors Covered in Report:
• Cancer Tyrosine Kinase
• Proteasome Inhibitors
• MTOR Protein Inhibitors
• Histone Deacetylase Inhibitors (HDAC inhibitors)
• PI3k

“Cancer Growth Inhibitors Market & Clinical Pipeline Analysis” Report Highlight:
• Introduction & Classification of Cancer Growth Inhibitors
• Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
• Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
• Markets Cancer Growth Inhibitors: 48 Drugs
• Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
• HDAC Inhibitors Clinical Pipeline: 65 Drugs
• MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
• PI3k Clinical Pipeline: 89 Drugs
• Proteasome Inhibitors Clinical Pipeline: 19 Drugs
• Global Cancer Growth Inhibitors Market Future Prospects

【レポートの目次】

1. Introduction to Cancer Growth Inhibitors

2. Classification of Cancer Growth Inhibitors

3. Cancer Growth Inhibitors Mechanism

4. Global Cancer Growth Inhibitors Market Overview
4.1 Current Market Scenario
4.2 Cancer Growth Inhibitors Clinical Pipeline Overview

5. Global Cancer Growth Inhibitors Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. Global Cancer Growth Inhibitors Market Future Prospects

7. Cancer Tyrosine Kinase Clinical Insight by Company, Indication & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase-I
7.6 Phase-I/II
7.7 Phase-II
7.8 Phase-II/III
7.9 Phase-III
7.10 Preregistration
7.11 Registered

8. Marketed Cancer Tyrosine Kinase Clinical Insight

9. HDAC Inhibitors Clinical Insight by Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Registered

10. Marketed HDAC Inhibitors Clinical Insight by Company & Indication

11. MTOR Protein Inhibitors Clinical Insight by Company, Indication & Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-III
11.8 Preregistration
11.9 Registered

12. Marketed MTOR Protein Inhibitors Clinical Insight by Company & Indication

13. PI3K Inhibitors Clinical Insight by Company, Indication & Phase
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-II/III
13.7 Phase-III

14. Marketed PI3K Inhibitors Clinical Insight by Company & Indication

15. Proteasome Inhibitors Clinical Insight by Company, Indication & Phase
15.1 Research
15.2 Preclinical
15.3 Phase-I
15.4 Phase-I/II
15.5 Phase-II
15.6 Phase-III

16. Marketed Proteasome Inhibitors Clinical Insight by Company & Indication

17. Competitive Landscape
17.1 Advaxis
17.2 Amgen
17.3 AstraZeneca
17.4 Bristol Mayer Squibb
17.5 Celldex Therapeutics
17.6 Eli Lily
17.7 GalaxoSmithKline
17.8 Genetech
17.9 ImmunoCellular Therapeutics
17.10 ImmunoGen
17.11 Merck
17.12 Novartis
17.13 Pfizer
17.14 Roche
17.15 Sanofi
17.16 Teva

Figure 1-1: Benefits of Cancer Growth Inhibitors
Figure 1-2: Functions of Cancer Growth Inhibitors
Figure 1-3: Improvement Required for Cancer Growth Inhibitor
Figure 2-1: Cancer Growth Inhibitors Classification
Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
Figure 3-1: Generalized Working of Cancer Growth Inhibitors
Figure 3-2: Mechanism of Bortezomib
Figure 3-3: Mechanism of Vismodegib
Figure 3-4: Mechanism of Everolimus
Figure 3-5: Mechanism of Bevacizumab
Figure 3-6: Mechanism of Imatinib
Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
Figure 4-5: HDAC Pipeline by Phase (%), 2015
Figure 4-6: HDAC Pipeline by Phase (Number), 2015
Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
Figure 4-13: PI3K Pipeline by Phase (%), 2015
Figure 4-14: PI3K Pipeline by Phase (Number), 2015
Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges
Figure 17-1: Advaxis Clinical Pipeline
Figure 17-2: Celldex Therapeutics Clinical Pipeline
Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline
Figure 17-4: ImmunoGen Clinical Pipeline


【掲載企業】

Advaxis, Amgen, AstraZeneca, Bristol Mayer Squibb, Celldex Therapeutics , Eli Lily, GalaxoSmithKline, Genetech.ImmunoCellular Therapeutics, ImmunoGen, Merck, Novartis
, Pfizer, Roche, Sanofi, Teva


【レポートのキーワード】

癌細胞増殖阻害剤、チロシンキナーゼ阻害薬、HDAC阻害薬、MTORタンパク質阻害薬、PI3K阻害薬、プロテアソーム阻害薬、医薬品、パイプライン分析、がん治療薬

★調査レポート[癌細胞増殖阻害剤の世界市場:チロシンキナーゼ阻害薬、HDAC阻害薬、MTORタンパク質阻害薬、PI3K阻害薬、プロテアソーム阻害薬] ( Cancer Growth Inhibitors Market & Clinical Pipeline Analysis / KUICK504221) 販売に関する免責事項
[癌細胞増殖阻害剤の世界市場:チロシンキナーゼ阻害薬、HDAC阻害薬、MTORタンパク質阻害薬、PI3K阻害薬、プロテアソーム阻害薬] ( Cancer Growth Inhibitors Market & Clinical Pipeline Analysis / KUICK504221) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆